Transcend Medical, Inc. (Transcend Medical), an ophthalmic device company, has appointed Sean Ianchulev as chief medical officer (CMO) and Ginger Clasby as vice president of clinical affairs. Ianchulev has extensive experience with medical devices. Most recently, he was associated with Genentech, Inc where he was the group medical director for the ophthalmology division and the Lucentis franchise.
In his role at Genentech, Ianchulev headed clinical development and medical affairs activities and was instrumental to the launch and success of Lucentis. As the founder of the Peristat Group, Inc., he developed the first diagnostic device for remote telemonitoring of visual function and disease management of patients with glaucoma and macular degeneration.
Ianchulev received his medical degree and a master’s of public health from Harvard University and completed his specialty training at the Doheny Eye Institute, University of Southern California. As a practicing ophthalmic surgeon and glaucoma specialist, he is well published in the field of ophthalmology and currently serves as an Assistant Clinical Professor of Ophthalmology at the University of California at San Francisco (UCSF).
Clasby is a seasoned medical device executive with varied, in-depth experience in clinical affairs, operations, quality assurance, and marketing. As an effective leader in both start-ups and large corporate environments, she brings critical knowledge and industry experience gained from more than 15 years serving executive level positions in operations and business development with Promedica International, a contract research organization. At Promedica International, she spearheaded the growth of the clinical regulatory division, establishing the company as a respected, major provider of clinical research services within the ophthalmic and medical device market sectors. Previously she served as vice president, marketing and sales at Optical Radiation Corporation and began her career with nearly a decade of experience at Allergan Medical Optics.